BioCentury | Feb 13, 2012
Company News

Bio-ID Diagnostics Inc., Trovagene deal

...of $0.75 on Feb. 7, the day before the deal closed (see BioCentury, Jan. 16). Bio-ID Diagnostics Inc....
BioCentury | Jan 16, 2012
Company News

Bio-ID Diagnostics Inc., Trovagene deal

...on tumor-specific mutations in a patient's urine. The deal is expected to close this quarter. Bio-ID Diagnostics Inc....
BioCentury | Mar 22, 2010
Company News

Enzo, Bio-ID Diagnostics sales and marketing update

...both panels next half. Further terms were not disclosed. Enzo Biochem Inc. (NYSE:ENZ), Farmingdale, N.Y. Bio-ID Diagnostics Inc....
Items per page:
1 - 3 of 3
BioCentury | Feb 13, 2012
Company News

Bio-ID Diagnostics Inc., Trovagene deal

...of $0.75 on Feb. 7, the day before the deal closed (see BioCentury, Jan. 16). Bio-ID Diagnostics Inc....
BioCentury | Jan 16, 2012
Company News

Bio-ID Diagnostics Inc., Trovagene deal

...on tumor-specific mutations in a patient's urine. The deal is expected to close this quarter. Bio-ID Diagnostics Inc....
BioCentury | Mar 22, 2010
Company News

Enzo, Bio-ID Diagnostics sales and marketing update

...both panels next half. Further terms were not disclosed. Enzo Biochem Inc. (NYSE:ENZ), Farmingdale, N.Y. Bio-ID Diagnostics Inc....
Items per page:
1 - 3 of 3